Abstract: Grease composition for constant velocity joints, comprising a base oil and a urea-based thickener, which grease additionally contains, (A) molybdenum sulphide dialkyldithiocarbamate and (B) 5,5-dithiobis(1,3,4-thiadiazole-2-thiol); a method of lubricating a constant velocity joint comprising packing it with said grease; and a constant velocity joint packed with said grease.

Abstract: To provide a lubricant which is excellent in the compatibility with ammonia and also has excellent practical performance such as good stability and lubricity.

Abstract: A synthetic ester-containing lubricant with good soot-handling and, with friction modifier, viscosity modifier and antioxidant present, improved engine performance and cleanliness.

Abstract: A heat-resistant, high-speed, high-load rolling bearing for automotive accessories and electric part is provided which develops no abnormal flaking and is sufficiently long in life and superior in durability. It is a heat-resistant, high-speed, high-load rolling bearing in which is sealed a grease composition which comprises a base oil which is a mixture alkyldiphenyl ether oil and aromatic ester oil at the ratio (in weight) of 50:50 to 80:20, a diurea compound expressed by the following formula as a thickening agent, and 0.1 to 5 wt % of a passivating agent.

Abstract: A perfluoropolyether, a composition comprising the perfluoropolyether, a process for producing the perfluoropolyether, and a process for improving the thermostability of grease or lubricant are provided. The perfluoropolyether comprises perfluoroalkyl radical end groups in which the radical has at least 3 carbon atoms per radical and is substantially free of perfluoromethyl and perfluoroethyl end groups.

Abstract: According to the present invention, there are provided a novel partial ester of a nitrogenous carboxylic acid ester with cellulose, the partial ester being useful as an antibacterial agent, a flame retardant, etc., and a simple and convenient process for preparing the same. Fibers made of said partial ester have washing-resistant antibacterial property and flame retardancy.

Abstract: A transparent soap bar comprising:

Abstract: The present invention provides a removable marking system that includes a removable paint formulation and an aqueous removal formulation, and a method of using this removable marking system.

Abstract: The invention relates to highly ethoxylated hydroxy mixed ethers, alone or in conjunction with customary detergent and cleaning product ingredients, together if desired with further nonionic surfactants and anionic surfactants, and to the use of such hydroxy mixed ethers for improving wetting behavior and plastics compatibility.

Abstract: The present invention relates to a process of cleaning a hard surface with a liquid acidic composition comprising a surfactant system, wherein said surfactant system comprises: a sulphated or sulphonated anionic surfactant; a neutralizing co-surfactant; and a sulfobetaine and/or an alkoxylated nonionic surfactant.

Abstract: The invention relates to an article containing (A) a water-insoluble substrate and (B) containing an aqueous phase and N-(3-chloroallyl)hexaminium chloride. According to one preferred embodiment of the invention, the composition also contains at least one C1-C4 alkyl para hydroxybenzoate and/or at least one ethylenediamine-tetraacetic acid salt. The article may especially constitute a wipe for cleansing and/or removing makeup from the facial and/or body skin, and also for removing makeup from the eyes. The wipe may be in the form of a moist or dry wipe.

Abstract: A granule with an allergenic component has reduced dust by including antifoam added during the production of the granule. The antifoam may be dispersed throughout the granule or added to one of the components of the granule. The granule with antifoam produces at least 30% less dust than a comparable granule produced according to a process in which no antifoam is added.

Abstract: The present invention relates to laundry detergent and cleaning product tablets which are distinguished both by high hardness, and thus stability in transit and on handling, and excellent disintegration properties. This advantageous profile of properties is achieved by the tablets comprising fatty alcohol alkoxylates and alkyl polyglycosides in the ratio defined by the invention.

Abstract: The invention relates to detergent tablets which are characterized in that they contain tenside granulates obtained by granulating and compacting non-ionic hydroxy mixed-ether-type tensides in the presence of disintegrants.

Abstract: Disclosed are pumpable surfactant compositions of alkanolamine salts of alkyl phosphate esters. The compositions have a solids content of about 60% by weight or more.

Abstract: A compound of the formula 1

Abstract: The invention relates generally to the treatment and inhibition of immunological complications of the eye. Such complications include unwanted immune responses resulting in an ocular inflammatory disease, resulting from a corneal or retinal graft transplantation or resulting from ocular angiogenesis, particularly ocular neovascularization. The invention relates in particular to the inhibition, treatment, or reversal of immune-system driven rejection of grafted corneal or retinal tissue or cells in a recipient host and to the treatment or inhibition of ocular inflammatory disease or ocular neovascularization in a host.

Abstract: Oxidative stress and inflammation often occur in the eye and often in association with aging or ocular disease. Increases in blood oxidative stress and inflammatory factors can be used to identify individuals with increased ocular oxidative stress and inflammation, select and guide appropriate interventions or treatments, identify selected patients for clinical study and/or determine the efficacy of various interventions or treatments. The present invention describes such factors and will improve the diagnosis, treatment and prevention of ocular oxidative stress and/or inflammation and related ocular conditions.

Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the transporter peptides, and methods of identifying modulators of the transporter peptides.

Abstract: Novel food, dietary supplement and nutraceutical products containing phenol/protein complexes derived from vegetable sources have high antioxidant activity and very high levels of protein. The products provide novel means for administering high levels of plant antioxidants to human and mammals in the form of a protein concentrate. Due to their high antioxidant capacity these novel products are useful as aids in the prevention and treatment of many diseases.

Abstract: A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugates. The mixture may also be more effective at surviving an in vitro model of intestinal digestion than polydispersed mixtures of similar conjugates. The mixture may also result in less inter-subject variability than polydispersed mixtures of similar conjugates.

Abstract: HHPDZ65 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HHPDZ65 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Abstract: The invention provides peptides designed to be highly reactive with antibodies from patients infected with oncogenic HPV. Also disclosed is a method for their use in an immunoassay to detect HPV infection and HPV associated epithelial cell abnormalities, most notably those associated with premalignant and malignant epithelial cell lesions. The peptides and the disclosed method are particularly useful for diagnosing carcinomas of the uterine cervix, or pre-stages thereof, or those at risk of development of carcinoma. The detection can be effected on blood samples, or other bodily fluid or tissue, by ascertaining the presence of IgA or IgG antibodies against HPV 16 and/or 18.

Abstract: The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.

Abstract: Polypeptides which stimulate bone growth: Gly Ile Gly Lys Arg Thr Asn Glu His Thr Ala Asp Cyc Lys Ile Lys Pro Asn Thr Leu His Lys Lys Ala Ala Glu Thr Leu Met Val Leu Asp Gln Asn Gln Pro and subsequences, particularly Arg Thr Asn Glu His Thr Ala Asp Cys Lys and associated nucleotide sequences, methods of preparation and use, antibodies and kits.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: Methods and compositions for the protection of white matter of the central nervous system. Specifically, the use of IGF-I, its analogs and mimetics, and the use of IGF-I, its analogs and mimetics in combination with interferons including beta 1 and consensus interferons, to stimulate glial cells such as mature astrocytes to promote remyelination to treat neuronal disease and injury, such as result from, for example, hypoxia, ischemia, trauma, degenerative and demyelinating diseases.

Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

Abstract: Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-11, and PYRIN-11 proteins, the invention further provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 fusion proteins, antigenic peptides and anti-PYRIN-2, -PYRIN-3, -PYRIN-5, -PYRIN-6, -PYRIN-7, -PYRIN-8, -PYRIN-10, and -PYRIN-11 antibodies. The invention also provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, or PYRIN-11 gene has been introduced or disrupted.

Abstract: The present invention provides methods of treating pathologic conditions associated with intestinal ischemia. In the methods, patients at risk for or suffering from intestinal ischemia are treated with a heparin-binding epidermal growth factor product.

Abstract: The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.

Abstract: A method for protecting white matter, axons, and oligodendrocytes of a mammal, especially a human, against degeneration and death resulting from multiple sclerosis or periventricular leucomalacia by increasing the effective concentration of a GPE-related compound in the central nervous system of the mammal. This increase may be achieved by administration to the mammal of an effective amount of a GPE-related compound, a prodrug thereof, or an implant containing cells that express the GPE-related compound or prodrug.

Abstract: Methods for using modulating agents to enhance or inhibit junctional adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. The modulating agents comprise at least one JAM cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds thee JAM cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

Abstract: New therapeutic uses for BPI protein products that involve treatment of subjects with a BPI deficiency condition, including selective BPI deficiency, and newborns, including BPI-deficient newborns.

Abstract: The present invention relates to regulation of IgE-receptor-mediated mast cell degranulation. More particularly, the present invention is directed to nucleic acids encoding CD43 (also called leukosialin or leukocyte large sialoglycoprotein), which is involved in modulation of IgE-receptor-mediated mast cell degranulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate IgE-receptor-mediated mast cell degranulation via modulation of CD43 and CD43-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to diseases such as allergies and asthma.

Abstract: A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases.

Abstract: The present invention describes a composition of matter comprising of a conserved structural motif that allows the targeting and binding of a chromatin binding protein to non-acetylated histone H3 and H4 and prevents their acetylation. This invention is responsible for the anti-carcinogenic property of a chromatin binding peptide isolated from soybean seed. This structural motif is found in a highly conserved manner in other chromatin-binding proteins from different species. Modifications to this structural motif such as fusions to other proteins with functional motifs and amino acid substitutions have potential therapeutic applications and can be developed as an in vivo gene silencing technology for biological and medical research. In particular, active fragments of the lunasin peptide and active analogs of the lunasin peptide are useful in this invention. Pharmaceutical compositions useful in retarding or stopping or reducing various types of cancers are described.

Abstract: Disclosed are methods, compositions, antibodies, and therapeutic kits for use in stimulating cytotoxic T-lymphocytes and generating immune responses against epitopes of protooncogenes. Novel peptides are described which have been shown to stimulate cytotoxic T-lymphocytes, and act as antigens in generation of oncogenic epitope-recognizing antibodies. Methods are disclosed for use in treating various proliferative disorders, and diagnosing HER-2/neu-containing cells; also disclosed are therapeutic kits useful in the treatment of cancer and production of potential anti-cancer vaccines.

Abstract: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is H-T-F-S-G-V-A-S-V-E and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD50 of 0.3-0.4 &mgr;M, while the LD50 for zinc-charged fetuin is 3-10 &mgr;M.

Abstract: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.

Abstract: This invention pertains to methods and compositions for inhibiting endothelial cell tube formation, the initial step of tumor angiogenesis. More specifically, the present invention relates to tripeptides that show inhibition of angiogenesis-mediated processes.

Abstract: A method of stimulating endogenous production of cytokines and hemopoietic factors by introducing to a mammalian body in need of stimulation of cytokines or hemopoietic factors or both, an effective amount of oxidized glutathione and/or its therapeutically beneficial salts, and/or its therapeutically beneficial derivatives, for a period of time to stimulate said endogenous production to obtain a therapeutic effect. Oxidized glutathione with or without extenders are used in drug forms.

Abstract: Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Abstract: The invention relates to a composition for topical application or oral administration, containing an effective quantity of at least one inhibitor of the enzyme 3&bgr;-hydroxysteroid dehydrogenase. This composition is designed in particular for the treatment of certain effects of chronological ageing and photo-ageing of the skin.

Abstract: New protein-polycation conjugates which are capable of forming soluble complexes with nucleic acids contain as their protein component an antibody directed against a cell surface protein, with the ability to bind to the cell surface protein so that the complexes formed are absorbed into cells which express the cell surface protein and are expressed therein. Complexes for use in pharmaceutical preparations contain a therapeutically or gene therapeutically active nucleic acid.

Abstract: Compounds and methods for the diagnosis and treatment of tuberculosis are disclosed. Compounds include the M. tuberculosis antigens Mtb-81 and Mtb-67.2, immunogenic portions thereof and polynucleotides that encode such portions. Such compositions may be used, for example, for the immunotherapy and serodiagnosis of M. tuberculosis infection.

Abstract: The present invention is directed to a method for detecting the presence or absence of any specific target nucleic acid sequence contained in a sample. The target sequence can be present in the sample in a relatively pure form or as a component of a member of a mixture of different nucleic acids. The method of the invention utilizes a novel primer design. The sequence of the novel primer is composed of two portions, the 3′ portion is a primer specific for the desired nucleic acid sequence and the 5′ portion is complementary to preselected nucleic acid sequence. Extension of the 3′ portion of the primer with a labeled deoxynucleosides triphosphate yields a labeled extension product if, but only if, the template includes the target sequence. The labeled extension product is detected by hybridization of the 5′ portion to the preselected sequence. The preselected sequence is preferably bound to a solid support as one member of a grid having a group of sequences.

Abstract: This invention relates to newly identified cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as “cancer antigens”, or alternatively “cancer related proteins”, and the use of such cancer antigens for detecting disorders related to the tissues where these cancer antigens are expressed, particularly the presence of cancer and cancer metastases. This invention relates to cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the tissues where these cancer antigens are expressed, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention.

Abstract: This invention provides a recombinant non-human animal lacking the cyclin-dependent kinase inhibitor function of p27Kip1 and the method for producing the same. This invention also provides a method for increasing the proliferation of the thymic T-cells by treating the thymic T-cells to eliminate the cyclin-dependent kinase inhibition function of p27Kip1. This invention also provides a method for increasing the proliferation of hematopoietic cells which comprises treating the hematopoietic cells to eliminate the cyclin-dependent kinase inhibitor function of p27Kip1, thereby increasing the proliferation of the hematopoietic cells. This invention further provides a method for alleviating symptoms of an AIDS patient comprising steps of: a) collecting the lymphocytes or other cells from an AIDS patient; b) treating the collected cells to eliminate the cyclin-dependent kinase inhibition function of p27Kip1; and c) re-introducing the treated cells to the AIDS patient.